IPPK activators comprise a targeted chemical class designed to enhance the activity of inositol pentakisphosphate 2-kinase (IPPK), an enzyme that plays a pivotal role in the biosynthesis of inositol polyphosphate signaling molecules. These signaling molecules are crucial for various cellular functions, including DNA repair, transcriptional regulation, RNA export, and apoptosis. By specifically increasing the enzymatic activity of IPPK, these activators aim to modulate the cellular levels of inositol polyphosphates, thereby influencing critical cellular processes and signaling pathways. The development of IPPK activators is driven by the potential to manipulate inositol polyphosphate signaling.
The initial phase in the development of IPPK activators involves high-throughput screening (HTS) of vast chemical libraries to identify compounds capable of enhancing IPPK activity. This screening process seeks to discover molecules that can bind to IPPK, increasing its catalytic efficiency or stabilizing the enzyme in an active conformation. Following the identification of potential activators, structure-activity relationship (SAR) studies are undertaken to refine these molecules, optimizing their potency, specificity, and pharmacological properties. SAR studies involve the systematic modification of the chemical structures of lead compounds and evaluating the impact of these changes on their ability to activate IPPK. Through iterative rounds of synthesis and testing, compounds are meticulously adjusted to improve their efficacy and selectivity for IPPK, while minimizing off-target interactions. Advanced techniques such as X-ray crystallography, nuclear magnetic resonance (NMR) spectroscopy, and molecular docking are employed to gain insights into the molecular interactions between IPPK and the activators, guiding the rational design of more effective molecules. Additionally, cellular assays are critical for assessing the biological activity of these activators in a physiological context, confirming their capacity to modulate inositol polyphosphate signaling pathways and elucidate their potential applications. Through a comprehensive strategy that combines targeted chemical synthesis, structural analysis, and functional validation.
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
8-Bromo-cAMP | 76939-46-3 | sc-201564 sc-201564A | 10 mg 50 mg | $126.00 $328.00 | 30 | |
8-bromo-cAMP is a cell-permeable cAMP analog. IPPK activity is regulated by cAMP-dependent protein kinase A (PKA). By increasing cAMP levels, 8-bromo-cAMP can activate PKA which in turn phosphorylates and activates IPPK. | ||||||
(−)-Epinephrine | 51-43-4 | sc-205674 sc-205674A sc-205674B sc-205674C sc-205674D | 1 g 5 g 10 g 100 g 1 kg | $41.00 $104.00 $201.00 $1774.00 $16500.00 | ||
Epinephrine is an adrenergic receptor agonist. Binding of epinephrine to its receptors activates adenylyl cyclase, increasing cAMP levels. This leads to PKA activation, which can phosphorylate and activate IPPK. | ||||||
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Forskolin is an activator of adenylyl cyclase, which increases cAMP levels. Elevated cAMP activates PKA, which can phosphorylate and activate IPPK. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
IBMX is a non-selective phosphodiesterase inhibitor which increases intracellular cAMP, activating PKA. Activated PKA can phosphorylate and activate IPPK. | ||||||
Rolipram | 61413-54-5 | sc-3563 sc-3563A | 5 mg 50 mg | $77.00 $216.00 | 18 | |
Rolipram is a selective PDE4 inhibitor, leading to increased cAMP levels. This activates PKA, which can phosphorylate and activate IPPK. | ||||||
Ionomycin, free acid | 56092-81-0 | sc-263405 sc-263405A | 1 mg 5 mg | $96.00 $264.00 | 2 | |
Ionomycin is a calcium ionophore that increases intracellular calcium levels. Elevated calcium levels can activate calmodulin, which can bind to and activate IPPK. | ||||||
A23187 | 52665-69-7 | sc-3591 sc-3591B sc-3591A sc-3591C | 1 mg 5 mg 10 mg 25 mg | $55.00 $131.00 $203.00 $317.00 | 23 | |
A23187 is a calcium ionophore that increases intracellular calcium levels. Increased calcium levels can activate calmodulin, which can bind to and activate IPPK. | ||||||
Cilostazol | 73963-72-1 | sc-201182 sc-201182A | 10 mg 50 mg | $109.00 $322.00 | 3 | |
Cilostazol is a selective PDE3 inhibitor, leading to increased cAMP levels. This activates PKA, which can phosphorylate and activate IPPK. | ||||||
Isoproterenol Hydrochloride | 51-30-9 | sc-202188 sc-202188A | 100 mg 500 mg | $28.00 $38.00 | 5 | |
Isoproterenol is a β-adrenergic receptor agonist, leading to increased cAMP levels. This can activate PKA, which then promotes IPPK phosphorylation and activation. | ||||||
Okadaic Acid | 78111-17-8 | sc-3513 sc-3513A sc-3513B | 25 µg 100 µg 1 mg | $291.00 $530.00 $1800.00 | 78 | |
Okadaic Acid is a potent inhibitor of protein phosphatase 2A (PP2A) and PP1. By inhibiting these phosphatases, Okadaic Acid can increase the phosphorylation and activation of IPPK. | ||||||